Podcasts about regulatory

In this episode, Etienne Nichols sits down with Staci Miller, a Human Factors and UX Strategist at GenUX, to demystify the role of human factors (HF) in the medical device regulatory pathway. Staci explains that many companies mistakenly treat HF as a "box-checking" exercise late in development, leading to costly submission delays or rejections when the FDA finds the documentation fails to tell a cohesive safety story.The conversation dives deep into the technical distinctions between a Use-Related Risk Analysis (URRA) and a User Failure Mode and Effects Analysis (uFMEA). Staci provides a framework for deciding which approach fits your product, emphasizing that while large conglomerates with post-market data may lean toward uFMEAs, startups and those with novel devices should prioritize the URRA to effectively map out user interactions without the crutch of existing market data.Finally, Staci addresses one of the most persistent myths in the industry: the idea that clinical trial data can replace human factors validation. She clarifies that while the two can overlap in specific, premeditated circumstances (such as complex implants like aortic valves), they serve entirely different masters—one focused on clinical efficacy and the other on the safety of the user interface across diverse environments.Key Timestamps04:12 – The common disconnect: Integrating Human Factors into ISO 14971 risk management.06:45 – URRA vs. uFMEA: How to choose based on your post-market data and predicate device status.10:30 – The "Definition of Done": Tracking the lifecycle of HF documentation from phase zero to market release.13:15 – System errors vs. Use errors: How to identify root causes during summative studies.18:50 – The "Clinical Trial Myth": Why efficacy data is not the same as usability validation.22:10 – Design Inputs vs. Design Outputs: The "Blueprint and the House" analogy for FDA submissions.25:40 – The impact of the "Use Environment": Testing for movement in ambulances and lighting in radiology suites.Quotes"The FDA doesn't put things out there just to have a good time... If they've made human factors a requirement and you're treating it as a 'suggestion,' you're giving yourself enough rope to hang yourself." - Staci Miller"People are obsessed with the product themselves—the design outputs. But the FDA wants to see the design inputs. They want to see the blueprints of how you built that house, not just the wallpaper." - Staci MillerTakeawaysPremeditation is Key: If you intend to use clinical trial data for HF validation, it must be planned in the protocol from the start; you cannot retroactively claim clinical data satisfies usability requirements.Map User Groups Early: Distinguish clearly between primary and secondary users. Bloating user sets without explaining how or why they engage with the device complicates your risk profile.Environment Matters: Documentation must account for the physical "10,000-foot view," including noise, lighting, and motion (e.g., an ambulance), as these are often where critical use errors occur.HF is Risk Management: Human factors should not live in a silo. It must align with the scales of harm (negligible to catastrophic) defined in ISO 14971 and work in tandem with Quality and Regulatory teams.ReferencesISO 14971: The global standard for the application of risk management to medical devices.FDA Human Factors Guidance: The primary document outlining expectations for usability testing and documentation.Etienne Nichols: LinkedIn ProfileMedTech 101: URRA vs. uFMEAThink of a uFMEA (User Failure Mode and Effects Analysis) like a car manufacturer looking at an old model to see why the brakes failed in the past—it relies on known data to fix specific parts.A URRA (Use-Related Risk Analysis) is like teaching someone to drive a brand-new type of vehicle (like a spaceship) for the first time. Since you don't have "crash data" yet, you have to carefully map out every single step the pilot takes and imagine every possible way they could push the wrong button in the heat of the moment.SponsorsGreenlight Guru: This episode is brought to you by Greenlight Guru, the only quality management platform designed specifically for the medical device industry. Whether you need to manage your QMS to stay compliant with ISO 14971 or streamline your clinical data through their EDC solutions, Greenlight Guru helps you move faster with less risk.Feedback Call-to-ActionWe want to hear from you! Do you have questions about your specific regulatory pathway or a topic you'd like us to cover? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, or suggestions to podcast@greenlight.guru.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and trends shaping the industry landscape, offering insight into the dynamic interplay between scientific innovation, regulatory challenges, and strategic growth.Starting with the recent departure of Vinay Prasad from the U.S. Food and Drug Administration, particularly from his role as director of the Center for Biologics Evaluation and Research (CBER). Prasad's tenure, though brief, left an indelible mark characterized by controversy and debate over regulatory decisions. His leadership coincided with significant advancements in biologics and gene editing technologies, like CRISPR, highlighting the complexities in balancing innovation with safety standards. Under Prasad's guidance, the FDA faced challenges in navigating these rapid advancements while maintaining rigorous oversight to ensure that new therapies are both effective and safe for public use. Prasad's resignation signals potential shifts in regulatory philosophy at CBER. The biotech industry is watching closely to see how new leadership will influence ongoing and future evaluations of biologics. The change presents an opportunity to reassess how regulatory bodies can better adapt to scientific advancements while ensuring that patient safety remains paramount. The issues faced during Prasad's tenure underscore the need for transparent decision-making and open communication with stakeholders, which are vital for maintaining trust in regulatory processes.Meanwhile, Pfizer has made a strategic entry into the Chinese obesity market with the approval of a GLP-1 drug developed alongside Sciwind Biosciences. This approval represents not only a significant step for Pfizer but also underscores a broader global focus on obesity management. The efficacy of GLP-1 receptor agonists in weight regulation has opened up new market opportunities, highlighting the growing importance of metabolic health solutions in addressing public health challenges.In other news, Johnson & Johnson's Tecvayli-Darzalex combination therapy has received its third national priority recognition from the FDA for treating multiple myeloma. This recognition reflects promising Phase 3 trial results and underscores the critical role of innovative combination therapies in improving outcomes for complex hematologic malignancies. The success of such therapies illustrates how targeted approaches can significantly enhance treatment efficacy and patient quality of life.Strategic acquisitions continue to reshape industry dynamics. Servier's $2.5 billion acquisition of Day One Biopharmaceuticals aims to strengthen its rare cancer portfolio, including a promising glioma drug, Ojemda. This move highlights Servier's commitment to addressing unmet needs in pediatric oncology and rare diseases, emphasizing a broader industry trend towards focusing on niche therapeutic areas with high potential impact.Regulatory activities are gaining momentum as well, with the FDA set to end a nine-month hiatus in advisory committee meetings by reviewing AstraZeneca's oral selective estrogen receptor degrader Truqa. As AstraZeneca seeks to enhance its oncology pipeline, this review signals ongoing innovation in hormone-based cancer therapies and reflects a renewed emphasis on bringing novel treatments to market efficiently.Additionally, Glenmark Pharmaceuticals has achieved a significant milestone with FDA approval for its generic version of GSK's asthma inhaler Flovent. This development exemplifies efforts to improve access to respiratory treatments by providing cost-effective alternatives to branded medications, potentially reducing healthcare costs while enhancing patient access.On an international scale, Taiwan has announced a substantial investment plan aimed at bolstering its drugSupport the show

Crypto markets are consolidating with Bitcoin dipping below $68K on macro headwinds like dollar strength and ETF outflows, while stablecoins like USDC surge in volume and nations like Kazakhstan eye crypto reserves. Regulatory wins in Florida and SEC settlements add to the mix. Prices remain resilient in the top tier despite volatility—watch for Fed signals and geopolitical impacts.Sources:https://decrypt.co (various stories on ETFs, mining, reserves)https://cointelegraph.com (USDC/Tether shift, SEC/Sun settlement)https://www.coindesk.com (BTC price action, Kazakhstan investment, private credit risks)https://coinmarketcap.com & https://www.coingecko.com (prices and market data) Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of developments that highlight the dynamism and complexity of our industry. The pharmaceutical and biotech sectors continue to evolve rapidly, driven by scientific innovations, regulatory shifts, and strategic initiatives.Eli Lilly's recent move to launch "Employer Connect," a platform aimed at improving access to its obesity medications, marks a significant step in addressing the growing public health issue of obesity. This initiative reflects the increasing influence of employer-driven healthcare solutions in managing chronic conditions. By directly involving employers, Eli Lilly seeks to enhance both the accessibility and affordability of its treatments, which could lead to better patient outcomes and reduced healthcare costs associated with obesity-related complications.In dermatology, Galderma has doubled its sales projections for Nemluvio (nemolizumab), an atopic dermatitis treatment, following a successful market debut. The revised projection to over $4 billion in peak annual sales underscores Nemluvio's strong market performance against competitors like Dupixent. This success not only highlights the drug's therapeutic efficacy but also indicates robust market demand for innovative dermatological therapies.Regulatory landscapes remain pivotal in shaping the industry. Vanda Pharmaceuticals' ongoing efforts to expand Hetlioz's label for jet lag treatment have been met with regulatory challenges since 2019. The FDA's response to Vanda's request for a public hearing underscores the complexities involved in navigating approval processes for label expansions. The outcome of such hearings could have broader implications for similar drugs seeking label amendments.Geopolitical dynamics also influence biopharma investments, with Ireland emerging as a stable manufacturing hub amidst global uncertainties. Despite geopolitical tensions, U.S. investments continue to flow into Ireland, highlighting its strategic importance as a location for biopharmaceutical manufacturing and innovation.In oncology, Pfizer is advancing its research and development strategy under Jeff Legos' leadership by leveraging its $43 billion acquisition of Seagen. The aim is to build an antibody-drug conjugate empire while advancing a PD-1xVEGF bispecific drug licensed from 3SBio. This approach underscores Pfizer's commitment to expanding its oncology pipeline through innovative therapies and combination regimens that could potentially transform cancer treatment paradigms.Meanwhile, Merck KGaA faces challenges with declining U.S. sales of Mavenclad due to anticipated generic competition. This situation reflects a broader industry trend where pharmaceutical companies must navigate patent expirations and generic market entries that threaten revenue streams of established products.Leo Pharma's launch of a direct-to-consumer campaign for Anzupgo, targeting hand eczema treatment, signifies the growing role of consumer engagement in pharmaceutical marketing strategies. Such approaches are becoming increasingly important in reaching patients directly.Collaborations remain a key driver of innovation within the industry. Daiichi Sankyo's partnership with German medtech Gaia to commercialize Lipodia—a digital therapeutic for high cholesterol management—illustrates the convergence between digital health technologies and traditional pharmaceuticals.In gene therapy news, uniQure finds itself in a contentious dialogue with the FDA over its Huntington's disease therapy. The debate centers around uniQure's claim that the FDA requested a "sham trial," which the agency denies. This situation underscores regulatory complexities surrounding gene therapies targeting rare diseases.Simultaneously, PepGen faces a partial clinical hold on its muscle wasSupport the show

In this episode of Scouting for Growth, Sabine VanderLinden welcomes industry veteran Karl Grandl, now of Miss Moneypenny Technologies, for a wide-ranging conversation on the real transformation underway in financial services and insurance.  Sabine VanderLinden sets the stage by emphasizing that digitization is no longer enough—true change means re-architecting operating models for velocity, intelligence, and trust at scale. Together, they explore the pitfalls of strategic complacency, the opportunities provided by European regulation, and the immense potential of intelligence layers and wallet technology to redefine how institutions interact with customers.  The discussion moves from strategic leadership to practical use cases—from frictionless onboarding and claims to agentic customer experiences—offering a roadmap for both incumbents and challenger firms looking to thrive in the era of real-time risk and embedded governance. KEY TAKEAWAYS Reflecting on my conversation with Karl Grandl, what became clear is that transformation in financial services isn't just about digitizing legacy systems—it's about fundamentally re-architecting the industry. For decades, institutions like banks and insurers were built for stability, but the pace of change and customer expectation today demands real-time, intelligent, and seamless experiences. Simply layering new digital tools over old processes leads to fragmentation, not progress. We're stepping into the era of frontier firms: organizations powered by intelligence, human-agent collaboration, and embedded governance. As Karl emphasized, automation by itself doesn't mean autonomy or intelligence. Instead, success hinges on evolving operating models and creating trust at scale. Regulatory changes, particularly in Europe—such as the EU AI Act and the introduction of digital identity wallets—are not burdens, but strategic advantages. They force discipline, drive infrastructure modernization, and create opportunities to offer frictionless experiences for 450 million citizens. Karl's insight into customer experience “activation layers” resonated deeply. True transformation is about orchestrating intelligent touchpoints so insurance feels invisible and effortless, yet highly trustworthy, especially at moments of service or claim. This approach preserves the value of brokers and advisors, enhancing their roles as strategic risk partners instead of replacing them. Finally, leadership, not technology, is at the heart of transformation. The ability to articulate a clear vision and quickly demonstrate value is what distinguishes the winners. Real-time governance, compliance by design, and empathetic human engagement are becoming essential to build—and keep—customer trust. The challenge for every executive now is not just to optimize yesterday's operations but to actively build tomorrow's intelligence layer. The frontier is being defined now, and it begins with a leadership mindset ready for structural redesign and velocity. BEST MOMENTS "Automation is not autonomy, efficiency is not intelligence, and digital channels without orchestration create digital fragmentation."  "European regulation is our unfair advantage. It's not just about discipline, it's about infrastructure."  "You have to evolve—from transaction intermediary into a strategic risk advisor, augmented by intelligence that handles routine so you can focus on relationships, empathy, and judgment."  "Governance is about to become the most strategic capability. When compliance agents and financial AI are embedded in every workflow, governance shifts from retrospective reporting to real-time intervention."  "The frontier firm is not defined by how much AI it deploys; it is defined by how intelligently it integrates risk, compliance, capital, and customer experience." — Sabine VanderLinden ABOUT THE GUEST Karl Grandl is often dubbed an “insurance dinosaur,” with over 30 years in the industry spanning Swiss Life, GetSafe, WeFox, and now Miss Moneypenny Technologies. His experience spans product development, distribution, and embedded insurance, as well as scaling tech-driven aggregators across markets.  At Miss Moneypenny, Karl is spearheading the integration of wallet technology and intelligence layers, focusing on frictionless customer interaction and embedding trust and compliance by design.  An advocate for regulation as a strategic advantage and transformation as a leadership imperative, Karl is a sought-after voice for both legacy insurers and challenger MGAs looking to build tomorrow's intelligence-driven operating models.  Connect with him via LinkedIn or at upcoming events such as InsurTech Week and InsurTech Insights in London. ABOUT THE HOST Sabine VanderLinden is a corporate strategist turned entrepreneur and the CEO of Alchemy Crew Ventures. She leads venture-client labs that help Fortune 500 companies adopt and scale cutting-edge technologies from global tech ventures. A builder of accelerators, investor, and co-editor of the bestseller The INSURTECH Book, Sabine is known for asking the uncomfortable questions—about AI governance, risk, and trust. On Scouting for Growth, she decodes how real growth happens—where capital, collaboration, and courage meet. If this episode sparked your thinking, follow Sabine VanderLinden on LinkedIn, Twitter, and Instagram for more insights. And if you're interested in sponsoring the podcast, reach out to the team at hello@alchemycrew.ventures

The global medical device regulatory environment is complex, often requiring manufacturers to repeat similar submissions and audits across multiple countries. This duplication slows innovation and delays patient access to life-saving technologies.To address this challenge, international regulators are increasingly collaborating through the International Medical Device Regulators Forum (IMDRF).In this podcast episode, Stephanie Grassmann (MedTechXperts) joins us to discuss how the concept of Regulatory Reliance is transforming global medical device approvals.What is IMDRF?The International Medical Device Regulators Forum (IMDRF) is a voluntary group of regulatory authorities working together to harmonize medical device regulations and reduce duplication across global markets.Members include major regulatory bodies such as:• United States (FDA)• European Union• Australia (TGA)• Brazil (ANVISA)• Canada (Health Canada)• China (NMPA)Their mission is to promote efficient regulation while maintaining high standards of safety and performance.Understanding Regulatory RelianceRegulatory reliance allows one authority to give significant weight to the work already performed by another trusted regulator.Instead of repeating full assessments, authorities can leverage existing evaluations, reducing regulatory burden while maintaining confidence in safety and effectiveness.Real-World Success StoriesSeveral regulators are already demonstrating the benefits of reliance mechanisms.Australia – TGAA Class III Mitral Valve Clip reached market access in just 20 working days after the regulator accepted evidence generated overseas.Argentina – ANMATDental instruments known as endodontic barbed broaches were approved in 9 working days using reliance pathways.Brazil – ANVISACompanies holding MDSAP certification may skip immediate on-site audits, saving both time and money during market entry.These examples show how regulatory cooperation can significantly accelerate approvals.The Role of MDSAPThe Medical Device Single Audit Program (MDSAP) allows manufacturers to undergo a single regulatory audit recognized by multiple countries.This program plays a key role in enabling reliance between regulatory authorities and reducing redundant inspections.The European PerspectiveEurope has historically maintained a distinct regulatory framework under EU MDR and IVDR.However, recent proposals—including references to Articles 108a and 108b—suggest increasing collaboration with international frameworks such as IMDRF and MDSAP.While a single global approval system remains a long-term goal, reliance initiatives are already demonstrating that cooperation between regulators can improve efficiency without compromising safety.Looking AheadFor manufacturers and startups, embracing international regulatory frameworks early—such as MDSAP and IMDRF guidance—can significantly improve global market access strategies.As regulatory collaboration grows, the future of medical device approvals may become faster, more harmonized, and more patient-centered.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.LinkStephanie Grassmann Linkedin: https://www.linkedin.com/in/stephaniegrassmann-medtechxperts/Social Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is powered by Podcastics, the easiest platform to create and publish your podcast.

How solid is your CMC foundation—and what happens if it cracks under pressure?David Brühlmann welcomes Henri Kornmann, former Head of Biologics Innovation Centre at Ferring Pharmaceuticals. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has moved repeatedly between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs.His “house building” approach demystifies CMC's complexity, showing why early diligence paired with regulatory fluency and scientific insight pays dividends for years.Tune in to hear Henri's practical wisdom distilled through real-world analogies:Building a strong CMC foundation in early phases and why later fixes can be costly or impossible (02:45)Scaling up: supplying Phase 3 with the final commercial process, including robustness and supply chain strategies such as dual sourcing critical raw materials (03:23)Process validation explained: FDA's three stages, from control strategy justification to continued verification (05:15)Process Performance Qualification (PPQ): what it is, how many batches are needed, and optimizing timing (07:43)Handling lifecycle changes: maintaining process control, adapting to deviations, and improving systems after regulatory approval (09:34)Managing teams, stakeholders, and cross-functional collaboration in CMC programs (11:49)Importance of good project management, access to scientific expertise, and interpreting guidelines for your specific program (12:27)The “half scientist, half lawyer” analogy for mastering both technical and regulatory aspects (15:08)Smart insight:Never underestimate CMC. If you do, you will pay for it later.If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC DevelopmentEpisodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene LeeEpisodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerConnect with Henri Kornmann:LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that highlight the intricate interplay of scientific innovation, regulatory dynamics, and strategic maneuvers shaping the industry.Starting with Moderna, the company has reached a pivotal resolution in a long-standing patent dispute involving its mRNA-based COVID-19 vaccine, Spikevax. This settlement involves a hefty $950 million payout to Genevant Sciences and Arbutus Biopharma, resolving claims of patent infringements. This agreement underscores the complex nature of intellectual property in the rapidly evolving mRNA landscape. Securing patent rights is crucial as new vaccines and therapies are developed, and this resolution not only clears a legal hurdle for Moderna but also exemplifies the industry trend towards resolving such disputes to foster continuous innovation.Sanofi has embarked on a significant strategic move by entering a $1.53 billion global licensing deal with Sino Biopharmaceutical. This agreement secures rights to a first-in-class JAK/ROCK inhibitor, which shows promise in treating hematological and immunological conditions. Such collaborations reflect the increasing focus on innovative therapies that target complex biological pathways, highlighting how companies are seeking unique assets to bolster their competitive edge.Regulatory scrutiny continues to be a formidable theme in the industry. The FDA has intensified its oversight on compounded GLP-1 drugs, issuing 30 warning letters to telehealth companies marketing unauthorized versions. This action highlights the agency's commitment to ensuring drug safety and efficacy while emphasizing the challenges companies face in navigating regulatory landscapes for compounded medications. Additionally, Novo Nordisk has been cautioned by the FDA regarding advertising practices for GLP-1 receptor agonists, illustrating the ongoing regulatory focus on pharmaceutical marketing strategies and compliance standards.Meanwhile, Bayer is experiencing a period of resilience in its pharmaceutical division, driven largely by its cancer drug Nubeqa and cardiovascular agent Kerendia. Despite these successes, Bayer faces challenges as revenues from older drugs like Xarelto and Eylea decline. This scenario reflects a broader industry challenge where companies must innovate while managing mature product lines facing generic competition.Teva Pharmaceuticals is making strategic strides by securing a $400 million deal with Blackstone to develop an anti-TL1A antibody for inflammatory bowel disease (IBD), in partnership with Sanofi. This investment highlights continued interest in autoimmune and inflammatory conditions as lucrative targets for novel therapies. Financial partnerships like Teva's substantial agreement with Blackstone illustrate how such collaborations can support sustained R&D efforts in chronic disease management.Technological integration into healthcare is expanding rapidly, with Nvidia collaborating with Droplet Biosciences to explore AI applications in medtech and cancer research. These partnerships illustrate an industry shift towards leveraging artificial intelligence to enhance diagnostic capabilities and accelerate research efforts. Moreover, collaborations leveraging AI/ML technologies across drug discovery pipelines are gaining traction; Earendil Labs partnering with WuXi XDC exemplifies this trend alongside Merck & Co.'s multi-year AI oncology data deal with Tempus—enhancing precision medicine capabilities while expediting therapeutic discoveries.In terms of funding new therapeutic areas, ARPA-H has announced a $158 million initiative aimed at developing medicines targeting the lymphatic system. This marks an exploration into less charted territories within physiological research that could yield transforSupport the show

Welcome back to Astronomy Daily! In S05E55, Anna and Avery explore six fascinating stories from across the cosmos — from auroras on Jupiter's largest moon to the latest JWST galaxy reveal, a breakthrough solar storm warning system, a beautiful combined nebula image, Japan's ongoing rocket struggles, and Europe's ambitious plans for orbital repair robots.   Stories This Episode 1. Ganymede's Auroras Mirror Earth's Northern Lights Scientists using data from NASA's Juno spacecraft have revealed that Jupiter's largest moon Ganymede has fragmented, patch-like auroras remarkably similar to those seen on Earth. The research, led by the University of Liège and published in Astronomy & Astrophysics, suggests that the fundamental physical processes generating auroras may be universal across magnetised bodies in the solar system. Ganymede is the only moon known to have its own intrinsic magnetic field. 2. New Solar Superflare Forecasting System An international team has developed the first system capable of predicting when and where extreme solar storms are likely to occur, with up to a year's advance warning. By analysing 50 years of X-ray data, researchers identified a 1.7-year and a 7-year solar cycle whose alignment predicts high-risk periods. The current window (mid-2025 to mid-2026) is flagged as elevated danger. Published in the Journal of Geophysical Research: Space Physics. 3. Cat's Eye Nebula — Euclid and Hubble Combined NASA and ESA have combined imagery from the Euclid and Hubble space telescopes to produce a breathtaking new composite view of the Cat's Eye Nebula — the glowing remnant of a dying star about 3,000 light-years away in Draco. The image showcases the nebula's complex layered shells and intricate inner structure in unprecedented detail. 4. JWST Reveals Spiral Galaxy NGC 5134 The James Webb Space Telescope has captured a stunning infrared portrait of NGC 5134, a barred spiral galaxy 65 million light-years away. Webb's infrared capability pierces through galactic dust to reveal glowing stellar nurseries and the full cycle of star birth and evolution playing out across the galaxy's spiral arms. 5. Japan's Kairos Rocket — Safety Abort on Third Attempt Space One's Kairos No. 3 rocket was aborted just 30 seconds before liftoff on March 4 when a safety monitoring system detected unstable positioning satellite signals. Following two failed launches in 2024 and multiple weather scrubs this week, the company has yet to set a new launch date. The window remains open until March 25. A successful launch would mark the first orbital success for a fully private Japanese rocket. 6. Europe's Orbital Repair Robots European companies led by Thales Alenia Space are developing robotic satellites capable of refuelling, repairing and repositioning spacecraft in orbit. A demonstration mission is planned for 2028. With nearly 15,000 operational satellites now in orbit — most never designed to be serviced — the in-orbit servicing market could transform how we manage space infrastructure. Regulatory questions around liability remain unresolved.   Links & Further Reading Full show notes, images and source links: astronomydaily.io Listen on: Apple Podcasts | Spotify | Amazon Music | All podcast platforms Watch on: YouTube — Astronomy Daily Follow us: @AstroDailyPod on Twitter/X, Instagram, Facebook, TikTok, Tumblr Part of the Bitesz.com Podcast NetworkBecome a supporter of this podcast: https://www.spreaker.com/podcast/astronomy-daily-space-news-updates--5648921/support.Sponsor Details:Ensure your online privacy by using NordVPN. To get our special listener deal and save a lot of money, visit www.bitesz.com/nordvpn. You'll be glad you did!Become a supporter of Astronomy Daily by joining our Supporters Club. Commercial free episodes daily are only a click way... Click HereThis episode includes AI-generated content.

Are reefer rates finally finding a new floor, and what does the Department of Labor's six-factor test mean for owner-operators?  Let's dive into the following topics: Vineland-to-Tracy reefer lane, where rates have stabilized around $4,500 despite winter slowdowns, signaling tighter capacity and a potential pricing shift for carriers and brokers.  The DOL's independent contractor rule changes and how the new test could reclassify drivers as employees, creating major liabilities if you're not careful.  The FMCSA's move to proactive safety enforcement using big data to flag high-risk carriers before incidents occur, improving safety while shaking up the competitive landscape.   Resources / References https://www.ttnews.com/articles/independent-contractor-rule https://www.overdriveonline.com/regulations/article/15818491/safer-transport-act-would-require-prosecution-of-fraudsters-more https://www.freightwaves.com/news/derek-barrs-defends-fmcsas-bold-moves-at-tca  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the pharmaceutical and biotech industries. The landscape continues to evolve with scientific breakthroughs, regulatory hurdles, and strategic alliances that have profound implications for drug development and patient care.Let's begin with Novo Nordisk's substantial investment of $500 million into an Ireland-based plant. This move reflects the ongoing demand for obesity treatments like Wegovy, a GLP-1 receptor agonist known for its efficacy in diabetes and weight management. The expansion aims to enhance production capabilities, particularly for markets outside the US, highlighting the global demand for such therapies. Recent studies in rodents suggest that GLP-1 medications may also support heart attack recovery by relaxing blood vessels, indicating broader cardiovascular benefits. This illustrates the multifaceted potential of GLP-1 receptor agonists beyond their primary indications.Turning to regulatory developments, the FDA has issued complete response letters to AstraZeneca and GSK, citing deficiencies in their data submissions. The feedback questions the data integrity of AstraZeneca's Saphnelo and the efficacy of GSK's Exdensur. These letters emphasize the importance of robust clinical evidence for achieving regulatory approval, underscoring the FDA's stringent standards. Such regulatory scrutiny highlights the necessity for pharmaceutical companies to ensure comprehensive and transparent data presentation.In strategic maneuvers within the industry, Esperion Therapeutics has acquired Corstasis Therapeutics for over $75 million, bringing the newly FDA-approved nasal spray Enbumyst into its portfolio. This acquisition illustrates ongoing consolidation trends aimed at diversifying product offerings and strengthening market positions in an increasingly competitive landscape.Meanwhile, DISC Medicine's decision to lay off 20% of its workforce following the FDA's rejection of a rare disease drug candidate underscores the volatility and risk inherent in drug development. This highlights the financial and operational challenges biotechs face when navigating complex regulatory pathways.Novo Nordisk and BioMarin have received FDA label expansions, allowing them to reach broader patient populations or offer additional therapeutic indications. Such expansions are crucial for enhancing treatment access and driving company growth. However, these advancements also reflect the challenges companies face in meeting evolving regulatory expectations while striving to expand their market footprint.Geopolitical tensions impact the industry as well, with companies closely monitoring employee safety and supply chain stability amid conflicts in regions like the Middle East. This situation highlights the vulnerabilities of global operations and underscores the need for robust contingency planning to maintain medicine access during crises.On the innovation front, Kyowa Kirin has discontinued its late-stage autoimmune disease program following cancer concerns linked to its anti-OX40 monoclonal antibody. This decision reflects the complexities of balancing innovative research with patient safety considerations. The discontinuation followed new cancer cases among participants receiving an anti-OX40 monoclonal antibody treatment, emphasizing the critical need for robust safety monitoring throughout the development process.Theravance Biopharma's substantial downsizing reflects similar challenges after a failed phase 3 trial for a blood pressure disorder drug led to significant corporate restructuring. This highlights how clinical setbacks can profoundly impact corporate strategy and employee livelihoods, serving as cautionary tales about resource investments required inSupport the show

In this episode, Rebecca Aston, Head of Professional Standards, and Adam Harper, Executive Director, Strategy, Advocacy and Professional Standards at the CII Group are discussing Continuing Professional Development, or CPD. They will be talking about the FCA's withdrawal of 15 hours under the Insurance Distribution Directive (IDD), the requirement for CII and PFS Members, and the process of CPD audits.

Dana Syracuse and Josh Boehm of Paul Hastings join the show. In this episode we discuss: The OCC Charter process how digital asset companies are pursuing the federal path The aftermath of the Genius Act passage and the rulemaking process for this law Considerations for Federal vs. State charter pathways The market structure bill Learn more about Paul Hastings 

It's huge, and serious.Its implications may impact millions, even beyond the halls of healthcare. In fact, it's the eighth-largest healthcare-related cybersecurity breach in U.S. history.In Texas alone, 15.4 million residents were involved – nearly half the state's population. Oregon reports another 10.5 million. Other states are still notifying residents. The final number may climb even higher. The stolen data reportedly includes names, Social Security Numbers, medical information, and health insurance details.Reporting the details of this enormous data breach during the next episode of Talk Ten Tuesdays will be the legendary Rose Dunn, former president of the American Health Information Management Association (AHIMA).Broadcast segments will also include these instantly recognizable panelists, who will report more news during their segments:POV: Penny Jefferson, Director of Coding & Clinical Documentation Integrity Services for the University of Davis Medical Center, will share her point of view during the broadcast.CDI Report: Cheryl Ericson will provide an update on clinical documentation integrity (CDI).The Coding Report: Christine Geiger will report on the latest coding news.News Desk: Timothy Powell, ICD10monitor national correspondent, will anchor the Talk Ten Tuesdays News Desk.

Seventy percent of FDA Complete Response Letters have a CMC root cause. Most of those failures trace back to decisions made years earlier. Decisions that felt minor at the time and proved impossible to fix later.Henri Kornmann has spent two decades making those decisions the right way. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has crossed between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs. His conclusion: a CMC program is like building a house. Get the foundation wrong and no amount of late-stage effort will save you.In Part 1, Henri reveals the decisions that cannot be undone and how to get them right from the start.What you will learn:Evolution of cell bank technology and regulatory expectations (00:33)The impact of weak CMC foundations on late-stage failure (00:51)Lessons learned from Ferring's gene therapy approval and CMC gap analysis (06:51)FDA statistics on CMC issues in INDs and response letters (08:07)Critical early decisions: cell bank clonality and proper storage practices (10:22)The importance of comprehensive raw material documentation (12:29)Early analytical characterization and discovering molecular “funkiness” before phase trials (13:41)Supply strategy for phase 2—why stability and batch knowledge matter (14:49)Introduction to critical quality attributes (CQA), process parameters, and quality-by-design principles (15:52)Common pitfalls in CQA identification and continued process verification (17:01)Smart insight:The therapies that reach patients aren't built on heroic late-stage rescues. They're built on disciplined early decisions: the right cell bank, the right analytics, the right documentation. Henri's message is unambiguous: there are CMC mistakes you can fix later, and there are CMC mistakes you cannot. Knowing the difference is the foundation of every successful biologics program.In Part 2, Henri walks through scale-up to commercial manufacturing, process validation stages 1 through 3, post-approval control strategy, and the project management and regulatory fluency that separate successful CMC leaders from the rest.If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC DevelopmentEpisodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene LeeEpisodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerConnect with Henri Kornmann:LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and ongoing challenges that are reshaping the landscape of these dynamic industries.A key highlight in recent developments comes from Ascendis Pharma, which has secured FDA approval for Yuviwel, a treatment targeting achondroplasia, a genetic disorder leading to dwarfism. This approval underscores the potential of Ascendis' "transient conjugation" drug delivery platform, marking its third rare disease drug approval in just six years. The platform's ability to extend drug half-life and improve dosing frequency highlights its promise in addressing unmet medical needs in rare diseases, offering new hope for patients who previously had limited treatment options.In oncology, Merck's LITESPARC clinical trial program is showing promising results with Welireg (belzutifan) for clear cell renal cell carcinoma. The trials suggest that combination therapies involving Welireg could set a new standard of care. However, transitioning these regimens into universal standards remains challenging due to competitive dynamics and hurdles in clinical adoption.Shifting to cardiovascular health, United Therapeutics has made notable progress with its phase 3 trial success for a once-daily drug candidate for pulmonary arterial hypertension. The trial reported a 55% reduction in clinical worsening risk, positioning United Therapeutics to seek FDA approval and potentially challenge existing treatments from major players like Johnson & Johnson.Regulatory challenges are also evident. UniQure recently faced a setback when the FDA rejected its data package for AMT-130, a gene therapy for Huntington's disease. This rejection reflects the stringent regulatory environment surrounding gene therapies and emphasizes the need for robust data to meet approval criteria.On the technological front, Eli Lilly is making a strategic shift by collaborating with Nvidia to integrate advanced computing capabilities into drug development. By leveraging Nvidia's AI-driven supercomputing power, Lilly aims to accelerate drug discovery processes and enhance precision medicine approaches, potentially transforming traditional pharmaceutical lifecycles.Operational shifts are also occurring as Merck winds down Gardasil production at its North Carolina plant due to declining global demand. This decision reflects broader vaccination trends and may signal shifts in manufacturing strategies to align more closely with market demands.Leadership changes at Bavarian Nordic, following a failed private equity takeover bid, indicate potential strategic realignments within the company. The planned departure of CEO Paul Chaplin after 12 years could herald new directions and priorities.In logistics, Frontier Scientific Solutions is pioneering advancements in temperature-controlled supply chains—crucial for maintaining drug efficacy during distribution. Their innovative approaches are reshaping pharmaceutical logistics, ensuring reliable delivery systems worldwide.Meanwhile, Walgreens is venturing into digital health with a virtual weight management clinic offering access to GLP-1 medications. This move positions Walgreens within the competitive telehealth market as it responds to growing consumer demand for convenient healthcare solutions.These developments collectively reflect an industry in flux—balancing scientific innovation with regulatory rigor and strategic realignments. As companies navigate these challenges, the implications for patient care are profound, promising potential improvements in treatment efficacy and accessibility.Turning our attention to Roche, another successful Phase 3 trial for fenebrutinib—a BTK inhibitor targeting relapsing multiple sclerosis—has been reported. The study achieved its primary endpoint but raiseSupport the show

Doug Crawford, Ph.D., is the founder of MBC BioLabs and also a Managing General Partner of Mission BioCapital. Doug's goal is to help entrepreneurial scientists create successful startups. His dream is that every entrepreneurial scientist with a dream be given a chance.  Since its founding, this program has helped launch 500 companies and helped raise over $20 billion in capital. Robert Blazej, Ph.D., is a Partner at Mission BioCapital and Director at MBC BioLabs. He is a passionate biotechnologist with a diverse skillset spanning business, life science, engineering and intellectual property. Robert Blazej brings 10 years of operational experience both as a successful entrepreneur and as a leader within an international corporation. Previously, Robert was CEO of Allopartis Biotechnologies, a company he co-founded with the vision that microdroplets would transform the scale and pace of life science research. Allopartis was acquired by Novozymes in 2013. This conversation can be considered as the 2026 State of the Union for early-stage biotech. The biotech landscape has shifted drastically- we moved from the grow-at-all-costs zero-interest-rate era to a world of tight capital and high discipline. The undisputed capital of biotech in Boston is facing unprecedented lab vacancies. AI is dominating every pitch deck. And China has rapidly evolved from a manufacturing hub into a multi-billion-dollar discovery engine.   Shownotes https://mbcbiolabs.com/; https://www.missionbaycapital.com/ How did Doug and Robert meet? Progress Mission Biolabs made in the past 4 years God's eye view of the biotech startup world- What is being built? DNA of the founders: repeat founders on the rise Capital restraints and advances in science made the current period the best time to launch biotech startups. With the advent of AI, we should not be making knowable mistakes Companies are using AI to jumpstart what they are going to work on Discovery costs are the overall cost of drug discovery- So, don't get too excited! How to address reduction in NIH non-dilutive funding ⅓ of startups in incubators are serial entrepreneurs; ⅓ are mid-career scientists from established companies  Comparing Boston and the Bay area biotech ecosystems 73% of pharma's revenues are from discoveries sourced externally Alternate models: Arena bioworks, Arc Institute, Chan Zuckerberg institute Book recommendation - Thinking in Bets Actual impact of AI at Mission Biolabs Where Ai might have the most impact- healthcare delivery? China affairs: Regulatory changes, investments, return of talent European biotech affairs

The Federal Communications Commission approved Charter Communications' acquisition of Cox Communications, making Charter a dominant broadband provider and reducing the number of internet service providers in many regions. This consolidation may decrease competition, limit consumer and business choices, and reduce incentives for service improvement and innovation. Businesses may experience changes in pricing, customer service, and network management, and should monitor for disruptions or policy shifts. With fewer ISPs, entrepreneurs and small businesses may have less bargaining power and face higher costs or fewer service options. Regulatory oversight remains important, and business owners are advised to stay informed about their rights, review ISP contracts, watch for service changes, consider alternative connectivity options, and engage with local associations and policymakers to advocate for increased competition and transparency. Research indicates that markets with more ISP competition offer better service and lower prices, while consolidation can make internet access less responsive to customer needs.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

In this episode, Ricardo explains that many projects fail not because of technical issues, but because the global context changes during execution. Elections, wars, sanctions, and trade tensions can shift priorities, block suppliers, and unexpectedly increase costs. Geopolitics goes beyond armed conflicts; it includes global supply chains, interest rates, exchange rates, and environmental regulations. Trade restrictions can halt infrastructure projects, export limitations can delay the delivery of critical equipment, and regional conflicts can raise material costs. Higher interest rates affect project financing, while currency fluctuations can quickly make contracts unviable. Regulatory changes also impact scope and timelines. So, project managers must include macroeconomic risks in planning, work with multiple scenarios, and involve leadership when the context changes to stay aligned with strategy in a globally unstable environment. Listen to the podcast to learn more!

The Centers for Medicare & Medicaid Services (CMS) has launched a new initiative titled Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH).CRUSH is a sweeping fraud prevention program. In an official news release posted Thursday, CMS reported suspending $5.7 billion in suspected fraudulent Medicare payments, preventing $1.5 billion in DMEPOS (Durable Medical Equipment, Prosthetics, Orthotics, and Supplies) billing, revoking more than 5,500 providers' billing privileges, and denying 122,000 claims that failed medical necessity checks.This latest news, including a nationwide DMEPOS enrollment moratorium and a $259.5 million Medicaid funding deferral, signals a decisive shift toward real-time enforcement.What does CRUSH mean for providers, revenue cycle leaders, and compliance teams?Senior healthcare consultant Penny Jefferson will be the special guest during the next live edition of the long-running news and information national podcast Monitor Mondays. Jefferson, the director of clinical documentation integrity (CDI) services for the University of California Davis Medical Center, will report on this new and developing story.The broadcast will also include these instantly recognizable features:Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.Legislative Update: Adam Brenman, senior legislative affairs liaison for Zelis, will report on current healthcare legislation.

In this episode of Current Account, Clay is joined by Doug Elliott, Partner at Oliver Wyman, and Andrés Portilla, Managing Director of Regulatory Affairs at the IIF, to take a closer look at the growing global debate over regulatory modernization. Fifteen years after the Global Financial Crisis led policymakers to introduce an expansive set of rules designed to reinforce financial stability, many jurisdictions are now questioning whether the existing framework has become overly complex, duplicative, or limiting to growth. Together, Clay, Doug, and Andrés unpack what modernization really means today, whether it is simplification, de‑layering, right‑sizing, or true deregulation, and why the conversation is gaining urgency across markets. Doug lays out the philosophical and practical forces behind modernization efforts globally, while Andrés discusses the findings of the recent IIF Report, "Modernization and Simplification — Revamping the Global Banking Regulatory Framework" - underscoring how overlapping constraints and diverging national interpretations create unnecessary friction for banks operating across borders. The discussion also turns to the ongoing debate over central bank independence, an issue increasingly intertwined with the regulatory modernization agenda. They examine how these debates differ across jurisdictions, how they may influence regulatory decision‑making, and why a credible, independent regulatory framework remains essential for market confidence. In addition, the conversation assesses the role of global standard setters, including the Financial Stability Board and the Basel Committee, in helping ensure consistency as countries revise their approaches at different paces. Clay and his guests discuss why maintaining coherence across borders is critical, even as national politics, growth priorities, and competitive pressures pull policymakers in different directions. This IIF Podcast was hosted by Clay Lowery, Executive Vice President, Research and Policy, with production and research contributions from Christian Klein, Digital Graphics and Production Associate and Miranda Silverman, Senior Program Assistant.

Part 1 explores how geopolitical divergence and shifting regulatory approaches are reshaping ESG risk in 2026. It highlights a more complex litigation landscape, growing use of novel arguments including attribution science and increasing claims linked to climate impacts, supply chains, human rights and allegations of greenwashing. Recorded as at 30 January.

Justin Lee is the founder of Ay Papi, a California-based craft cannabis company focused on solventless, single-origin products made in collaboration with regenerative legacy cultivators.Before entering the cannabis industry, Justin worked in entertainment as an actor and producer, and competed as an MMA fighter. His path into cannabis was shaped by firsthand experience with injury, chronic pain, and recovery, which led him to explore cannabis not just recreationally, but as part of a broader, more intentional approach to health and wellbeing.Ay Papi operates without outside capital and rejects volume-driven models, tier systems, and artificial flavouring. Instead, the brand centres genetics, farming practices, and flavour as expressions of place, people, and process. In 2024, Ay Papi's Whitethorn Rose Single Origin Live Rosin Infused Gummies received Gold and the Golden Bear at the California State Fair, recognised for doing the opposite of most edibles: allowing the cannabis itself to define the experience.Justin is also a certified Ganjier and a vocal advocate for solventless production, regenerative agriculture, and greater cannabis literacy. His work sits at the intersection of culture, craft, and responsibility, with a strong emphasis on honouring farmers, hashmakers, and the systems that make high-quality cannabis possible.In this episode:Justin Lee on being Annyong on Arrested Development (2:00)Abbott Elementary cannabis activation (6:30)Cannabis as medicine: overcoming concussion, ceasing opioids and bio-hacking (9:00)Self-care to Ay Papi (19:00)What does craft mean? (23:00)What does organic and regenerative mean? (27:00)Live Rosin (32:00)Quiz: Hellos around the World (39:30)Real time habit changes (41:30)Regulatory and industry changes needed in California (43:00)Will rescheduling happen? (45:00)Pauls of Wisdom (48:00)Follow @yoswaggylee on InstagramFollow @aypapico on InstagramVisit https://aypapi.co/Visit www.giveandtoke.com.auFollow @giveandtoke on InstagramEmail giveandtoke@gmail.com

The New York Times says crypto is finished. CNBC runs with it. Meanwhile Bitcoin search interest just hit a five year high and price rips 10 percent in a day. This is not a funeral. It is separation season, where hype dies and Bitcoin keeps producing blocks.Regulatory clarity is forming, supply is tightening, and capital is positioning. The question is not whether crypto is dead. The question is whether you are ready for the next move.SPONSORS:

In this week's episode, Elliot Berman and John Byrne cover a wide-ranging set of developments reshaping the global AML landscape. They open by marking the fourth anniversary of Russia's invasion of Ukraine before diving into new regulatory, enforcement, and geopolitical stories affecting financial crime professionals. John highlights the Federal Reserve's request for comment on removing “reputation risk” from bank supervision and discusses ongoing litigation involving JPMorgan and the Trump Organization. The conversation then turns international: OCCRP's newly announced Anti-Corruption Hero Awards, revelations of European-made parts ending up in Russian military drones, and the European Center for Not-for-Profit Law's work on financial access for human rights defenders. Elliot and John also examine Australia's transition to a new AML/CFT regime and Canada's new financial intelligence initiative focused on extortion. Additional topics include the Treasury Inspector General's audit of FinCEN, IRS-CI's latest BSA data usage report, and U.S. cases involving cyber intrusions and tax fraud.

In this inaugural episode of Season 10, Amy Wheeler introduces the guiding framework for the year ahead: exploring the Eight Limbs of Yoga as a practical, integrated regulatory framework for the autonomic nervous system. Rather than offering “tools and tricks” for stress, this season centers a wider view—how yoga shapes the conditions for safety, stability, adaptability, and coherence across daily life. Amy explains why nervous system regulation matters across integrative health contexts. When we support autonomic balance, we support the whole person—how we sleep, digest, think, relate, decide, and recover from chronic stress and burnout. This season also bridges personal practice and professional application, supporting listeners who want yoga to be a private anchor, and those discerning how yoga therapy can responsibly integrate into healthcare, education, and community settings. A key reframe anchors the episode: the Eight Limbs are not a ladder to climb, but a circle with eight doors. Each limb is an entry point, and once you enter, every practice influences the whole system—physiology, perception, behavior, relationships, and purpose. Season 10 also aligns with Amy's forthcoming book (with Marlisa Sullivan), Applications of Therapeutic Yoga in Integrative Health(anticipated late spring/early summer 2026), designed as a companion guide to help practitioners translate yogic principles into accessible language for real-world settings. In This Episode, Amy ExploresWhy the autonomic nervous system is a shared meeting point between yoga and integrative healthcareThe Eight Limbs as a regulatory framework, not simply a set of techniquesHow regulation affects perception (viveka), behavior, communication, and ethical decision-makingWhy “coherence” matters: aligning life demands with inner and outer resourcesThe Eight Limbs as a circle with eight doors—interrelated, non-hierarchical entry pointsThe yamas and niyamas as the ethics of regulation, not moral perfectionHow yoga therapy differs from fitness-based yoga: assessment, client-centered care, scope, and responsibilityWhy this season includes more solo teaching episodes, with select guests across disciplinesHow listeners can develop simple language and metaphors (like the stoplight model) to explain regulation Invitation for the SeasonAs you listen this year, consider tracking phrases, metaphors, and explanations that help make complex ideas accessible. This season is designed as a shared learning laboratory—supporting personal regulation, while also strengthening the collective capacity to communicate clearly about yoga therapy in integrative health spaces. Host: Amy Wheeler at www.TheOptimalState.comAbout: Chair, Yoga Therapy & Ayurveda Department, Notre Dame of Maryland UniversityAlso Featured: insights informed by Amy's work with the Polyvagal Institute Subscribe, Share, and Stay ConnectedIf this season supports your personal practice or your professional path, consider subscribing, sharing an episode with a colleague, and following along as the series unfolds across 2026. School of Integrative Health at NDMU: https://www.ndm.edu/academics/integrative-healthMaster of Science in Yoga Therapy at NDMU https://www.ndm.edu/academics/integrative-health/yoga-therapy Explore NDMU's Post-Master's Certificate in Therapeutic Yoga Practices  https://www.ndm.edu/academics/integrative-health/yoga-therapy/post-masters-certificate-in-therapeutic-yoga-practices Try our Post-Bac Ayurveda Certification Program at NDMU: https://www.ndm.edu/academics/integrative-health/ayurveda/post-baccalaureate-ayurveda-certification#IntegrativeHealth #HealthcareEducation #InterprofessionalEducation #GraduateSchool #NDMUproud #SOIHproud #SOIHYoga #SOIHAyurveda #NDMUYoga #NDMUAyurveda #SOIHGraduateSchool  Yoga Therapy Hour Podcasthttps://podcasts.apple.com/us/podcast/yoga-therapy-hour-with-amy-wheeler/id1564687158 The Optimal State Mobile Apphttps://optimalstateapp.com

First, San Diego Gas and Electric profits fell by a third because of a large, one-time charge. Also, Escondido City Council has chosen to continue letting federal immigration officers train at a city-owned firing range. Then, the federal government swiftly responded to a sewage spill in the Potomac River, with some local residents living near the San Diego-Mexico border saying they feel left behind. And, we tell you about a sports competition where winning isn't the priority. Last but not least, we share some weekend events happening across the county for you and yours to possibly take part in! Correction: A previous version of this story said without the disallowance, SDG&E would have made close to $1 billion in profit. According to their spokesperson, that is incorrect.

Ep.329International investing had a strong 2025, and 2026 is off to a promising start. But when we say “international,” what are we really talking about?Developed markets? Emerging markets? Europe? Asia?In this episode, Gabriel Shahin, CFP®, breaks down the real difference between Asia and Europe as investment regions—and why he's currently more bullish on Asia.Here's what we cover:• Why Europe had a strong 2025—but what actually drove those returns• How 60% of Europe's gains came from financials and industrials• The role of deregulation hopes and a strengthening yield curve• Why Asia's returns were driven by tech and communications• The massive earnings growth gap (20–29% in Asia vs ~4% in Europe)• How AI, semiconductors, digitalization, and innovation are shaping Asia• Taiwan Semiconductor vs ASML—valuation and growth comparison• Why demographic decline and overregulation weigh on Europe• How cultural momentum and government support fuel Asian growth• ETF exposure examples for diversified international positioningIt's not about loving one continent over another—it's about capital allocation.Asia is positioned around:– AI infrastructure– Semiconductor dominance– Digital expansion– Energy transition– Supply chain innovationEurope, while home to strong brands and select standout companies, faces:Slower earnings growth– Aging demographics– Regulatory friction– Higher structural energy costsThat doesn't mean avoid Europe entirely—but it does mean understanding where future growth is likely to accelerate.

For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases. But the application of these engineered cell therapies is expanding to reset the immune system for patients living with lupus, stiff person syndrome and other autoimmune conditions. And with new frontiers come new rules. In this week’s episode of "The Top Line," Fierce Pharma’s Angus Liu chats with Harpreet Singh, M.D., chief medical officer at Precision for Medicine and a former director of the FDA's Division of Oncology, about a recent article by FDA officials led by CBER Director Vinay Prasad, M.D., laying out the agency’s perspective on its regulation of autoimmune CAR-T therapies. Singh discusses how the agency’s "case-by-case" approach, as indicated in the article, could be similar to—and different from—CAR-T for oncology indications. She also talks about how drug developers should follow existing development experience, as well as prepare for specific requirements for long-term patient follow-up and potential new clinical endpoints from the agency. To learn more about the topics in this episode: FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some pivotal advancements and strategic shifts within the industry, highlighting how these changes are shaping the future of patient care and drug development.Let's start with Bristol Myers Squibb, which has been making headlines with its latest success in the realm of antibody-drug conjugates (ADCs). The company's ADC has reached an important milestone in a Phase 3 breast cancer trial conducted in China. This study successfully met its dual primary survival endpoints, affirming the company's significant $800 million investment in this promising drug candidate. The potential of ADCs in oncology cannot be overstated; they offer a remarkable combination of targeted therapy by harnessing the specificity of antibodies alongside the cytotoxic power of traditional chemotherapy. This approach not only enhances precision in treatment but also minimizes collateral damage to healthy tissues, showcasing the transformative potential of ADCs in cancer therapy.On the regulatory front, there are ongoing discussions about the impact of political decisions on drug pricing and innovation. The Trump administration's Most Favored Nation drug pricing policy has stirred significant concern within the biotech sector. In response, ten midsize biotech firms have united to form the Midsized Biotech Alliance of America to challenge this policy. They argue that such pricing strategies could hinder innovation by enforcing restrictive pricing models, potentially stalling the development pipeline for new therapies that address unmet medical needs.In terms of strategic corporate movements, Boehringer Ingelheim has entered into a $500 million partnership with a British biotech firm aimed at developing an oral therapy for autoimmune diseases. This collaboration is part of a broader trend towards precision medicine which focuses on modulating specific immune cells to improve treatment outcomes while minimizing unwanted side effects. It's a clear indication that companies are increasingly investing in targeted therapies that promise better efficacy and patient safety. Additionally, Boehringer Ingelheim's partnership with Sitryx underscores another trend: strategic partnerships aimed at innovative research endeavors with substantial investment commitments—potentially exceeding $500 million—to explore immune response modulation.The acquisition landscape is also seeing dynamic shifts. Asahi Kasei's acquisition of Germany's AiCuris for $920 million marks a strategic move to enhance its R&D capabilities, specifically focusing on antiviral therapies for immunocompromised patients. This acquisition aligns with growing global attention towards infectious disease research, especially in a post-pandemic era where preparedness and rapid response capabilities have become paramount.Meanwhile, Sarepta Therapeutics is undergoing a significant leadership change as CEO Doug Ingram announces his retirement. Ingram's leadership was characterized by notable advancements in treatments for Duchenne muscular dystrophy (DMD), although it wasn't without its share of challenges regarding regulatory and pricing debates. As Sarepta continues to expand its gene therapy pipeline, this leadership transition comes at a crucial juncture, potentially setting new directions for the company's future.Accent Therapeutics' recent decision to halt its solid tumor trial due to adverse events exemplifies the risks inherent in drug development. The company is now redirecting its focus towards other cancer programs, illustrating how adaptability remains key in navigating clinical setbacks.Protagonist Therapeutics has made a strategic choice by accepting a $400 million payment from Takeda instead of sharing profits from its hematology asset rusfertide. This decision may provideSupport the show

Clinicians saying they love your product doesn't mean hospitals will adopt it — and that gap is where clinician-led MedTech companies burn cash and lose momentum.In this episode, Hakeem is joined by Mark Tudor (20+ years in commercial leadership and advisory roles in medical devices) to break down why technically strong products stall after launch, how hospitals really decide what to buy, and how to build the commercial foundations that drive adoption, sales, and export readiness.Learn why commercial planning must run in parallel with product and regulatory workUnderstand what hospitals actually buy (risk management, simplicity, and economic clarity — not “better performance”)Get a practical lens for stakeholder mapping, validation beyond friendly opinions, and avoiding “inventor syndrome”Helping clinicians simplify their go-to-market strategy so they can stop guessing and turn their working prototypes into international MedTech businesses.Decision point scenario: You're advising a clinician founder with regulatory approval, two pilot sites, one keen-but-unproven distributor, limited runway, and 90 days before board pressure. You can only prioritise one focus — what do you choose and why? (Mark answers in the next episode.)If you tell me whether you want this episode to lean harder into adoption, hospital buying decisions, or export/distributor readiness, I'll pick the best 3 titles from above and tighten them even more.Message me via DM on LinkedinBook a 30 min discovery call for the Healthcare Export Accelerator ProgrammeThis podcast is for clinicians turning medical devices into real businesses, with practical insight on go to market strategy, exporting, and scaling in international MedTech.

In a recent episode of the award-winning Consumer Finance Monitor podcast, Alan Kaplinsky was joined by Nick Bourke, Kate Griffin, and Ballard Spahr partner Joseph Schuster to discuss a groundbreaking new report from the Aspen Institute Financial Security Program: United We Stand: A National Strategy to Prevent Scams. The episode builds on Nick and Kate's prior appearance on the podcast last July, when the report was still in development. Now finalized, the report offers one of the most comprehensive frameworks to date for addressing what has become a systemic threat to American households and the broader financial system. The Scope of the Problem: A Systemic Threat Frauds and scams are no longer isolated consumer protection issues. According to the report, U.S. households are losing an estimated $196 billion annually to scams — roughly $1 billion every couple of days. One in five American adults reports having lost money to an online scam. As Nick Bourke explained, today's scams are: ·                 Technology-enabled ·                 Highly organized and industrialized ·                 Often operated by transnational criminal organizations ·                 Accelerating due to AI and faster payment systems The so-called scam "lifecycle" includes four stages: 1.     Lead – Hooking the victim 2.     Deceive – Building trust (often through impersonation or relationship-building) 3.     Bleed – Extracting funds 4.     Clean – Laundering proceeds, often through cryptocurrency or offshore channels Different sectors see only fragments of this lifecycle; social media platforms may see the "lead," financial institutions the "bleed," and law enforcement the "clean." That fragmentation allows criminals to scale operations while defenders remain siloed. Why Scams Are Rising Despite Heavy Investment As Kate Griffin noted, industry and government are investing heavily in prevention. Yet scams continue to grow. Why? ·                 Fragmentation across sectors: No single actor sees the entire attack sequence. ·                 Outdated reporting infrastructure: Federal systems at agencies like the FBI and FTC remain manual and technologically antiquated. ·                 Regulatory uncertainty: Financial institutions and technology platforms face unclear expectations about what data they can use and share. ·                 Speed of modern payments: Faster money movement means faster losses. Joseph Schuster emphasized that many financial institutions are strongly incentivized to prevent fraud as they often bear reputational and financial risk when scams succeed. But legal ambiguity, especially under statutes like the Fair Credit Reporting Act, can chill data-sharing and innovation. Core Recommendations from the Aspen Report The report outlines both high-level national reforms and granular operational improvements with more than 180 specific ideas. 1. Elevate Scam Prevention to a National Priority The report calls for: ·                 A designated federal lead (or "czar") to coordinate strategy ·                 A whole-of-government approach ·                 Clear national goals and metrics Without centralized leadership, enforcement and regulatory actions remain fragmented.  2. Modernize Law Enforcement Reporting Systems Federal reporting portals, including Suspicious Activity Reports (SARs), the FBI's complaint systems, and the FTC's databases, require modernization. The report recommends: ·                 Streamlined, automated reporting ·                 Backend data interoperability across agencies ·                 Advanced analytics and AI tools for enforcement 3. Establish Clear Duties to Act Paired with Safe Harbors One of the most important themes discussed was the need for: ·                 Clear expectations for banks, telecom companies, and digital platforms ·                 Safe harbors that protect companies when sharing scam intelligence in good faith Countries like Australia have already codified such frameworks. The U.S. has yet to establish similarly coordinated standards. 4. Build a Cross-Sector Information-Sharing Ecosystem Effective scam prevention requires: ·                 Exchange of scam indicators (malicious URLs, compromised phone numbers, device patterns) ·                 Interoperable information-sharing platforms ·                 Privacy-preserving architecture ·                 Legal clarity to mitigate antitrust and consumer reporting concerns Joseph noted that industry appetite for collaboration is strong but clarity and guardrails are essential. 5. Consider a U.S. National Anti-Scam Center The report explores the idea of a centralized "front door", potentially something like stopscams.gov, that would: ·                 Serve as a national reporting hub ·                 Provide victim resources ·                 Facilitate coordination among law enforcement ·                 Support public education campaigns Social Media and Platform Responsibility The discussion also addressed the evolving role of digital platforms. Scam activity frequently originates through: ·                 Paid advertisements ·                 Dating applications ·                 Direct messaging ·                 Fake investment websites Compared to banks, social media companies operate within a less clearly defined regulatory structure. Courts are increasingly developing theories of "platform liability," but statutory clarity is lacking. The report urges policymakers to define reasonable expectations for platforms — paired with safe harbors and practical tools that empower prevention rather than merely assign blame. What Happens Next? The key question: who implements this strategy? Kate Griffin emphasized that this is a whole-of-society problem requiring coordinated action by: ·                 Federal leadership ·                 Congress ·                 Financial institutions ·                 Telecom and digital platforms ·                 Law enforcement ·                 Civil society There have been encouraging developments, including: ·                 Treasury and State Department sanctions targeting transnational scam networks ·                 A joint DOJ–FBI–Secret Service initiative targeting Southeast Asian scam operations o   But much more remains to be done. Nick Bourke suggested that, one year from now, real success would include: ·                 A designated federal anti-scam lead ·                 A congressional commission ·                 Measurable national prevention goals ·                 Corporate adoption of formalized anti-scam strategies Joseph Schuster added that industry innovation is ongoing, particularly in artificial intelligence, biometrics, and authentication, but warned that fragmented state-level regulation could complicate progress. Key Takeaways Alan Kaplinsky closed the episode with several important observations: ·                 Fraud and scams are now a systemic threat, not a niche compliance issue. ·                 Prevention, not just reimbursement, must be the organizing principle. ·                 Coordination matters as much as authority. ·                 Good-faith companies need regulatory clarity, not just enforcement pressure. ·                 Reducing scams strengthens trust in the U.S. financial system and digital economy. The Aspen report reframes the debate. Rather than assigning blame, it calls for aligned incentives, shared responsibility, and coordinated national action. If the title of the report, United We Stand, becomes reality, the United States may finally begin to bend the curve on one of the most costly and fast-growing threats facing consumers today. For more insights on consumer financial services developments, visit Ballard Spahr's Consumer Finance Monitor blog and explore the full Aspen Institute report here. Consumer Finance Monitor is hosted by Alan Kaplinsky, Senior Counsel at Ballard Spahr, and the founder and former chair of the firm's Consumer Financial Services Group. We encourage listeners to subscribe to the podcast on their preferred platform for weekly insights into developments in the consumer finance industry.

IEC 60601 has been central to medical electrical equipment safety for decades. From the prescriptive approach of the 2nd edition to the risk-based philosophy introduced in the 3rd edition, the standard has continuously evolved to address technological and regulatory complexity.Now, the upcoming 4th edition represents more than an amendment — it signals a structural transformation.This article explores:The Evolution of IEC 60601• Key shifts from the 2nd to the 3rd edition• Why risk management became central• What lessons shaped today's safety philosophyWhat the 4th Edition Brings• A major rewrite rather than incremental updates• The introduction of “atomic requirements”• Structural clarity for manufacturers, test labs, and regulators• Emerging technical considerations (digitalization, AI, cybersecurity, home use)Impact on Existing Devices• Will re-testing be required?• How to assess validity of existing test reports• Transition strategies with notified bodiesIntegration into Design & Documentation• Embedding IEC 60601 into risk management from day one• Required updates in risk files, EMC documentation, labeling, and usability engineering• Practical advice for SMEs with limited resourcesThe Future of IEC 60601• Greater harmonization with ISO 14971 and IEC 62304• Alignment with digital and AI regulatory frameworks• The long-term outlook for medical electrical safetyFor manufacturers, the message is clear:IEC 60601 is not just a testing standard — it is a design and risk management framework that must be integrated early and strategically.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.LinkLeo Linkedin: https://www.linkedin.com/in/leoeisnersafetyconsultants/Social Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is powered by Podcastics, the easiest platform to create and publish your podcast.

hema.to is building AI-powered diagnostic infrastructure for cytometry—a specialized area of laboratory medicine analyzing immune system data to detect blood cancers like leukemia and lymphoma. Unlike radiology or pathology where AI solutions are abundant, cytometry has remained largely untouched by the AI wave, creating both opportunity and isolation for the Munich-based company. In a recent episode of BUILDERS, we sat down with Karsten Miermans, CEO at hema.to GmbH, to discuss why they're deliberately keeping sales founder-led despite having paying customers, how South America became an unexpected beachhead market, and what it actually means to build infrastructure versus point solutions in healthcare. Topics Discussed:  From consulting project to venture-backed company: recognizing scalability in hindsight  The workflow integration problem killing healthcare AI implementations  Infrastructure versus technology: why healthcare AI isn't just about the algorithm  Learning ideal customer profile after 18 months of being "all over the place"  Why South America's governance structure enables faster adoption than the US  Resisting the urge to hire sales before achieving true repeatability  The 10-year vision: shifting from "watch and wait" to "predict and prevent" in immune disease GTM Lessons For B2B Founders: Pattern matching fails when you're an outsider—budget 18+ months to find your beachhead: Karsten assumed every application of their diagnostic method was the same and spent a year and a half "blue eyed" (naively optimistic) before identifying their true ICP. The outsider advantage lets you reimagine workflows insiders can't, but you'll incorrectly assume transferability across use cases. Don't expect repeatability in year one when entering regulated, workflow-dependent markets. Infrastructure requires multi-stakeholder orchestration—resource for enterprise complexity from day one: Karsten distinguishes technology (point solutions, single users) from infrastructure (shared resources requiring data exchange and workflow integration). In healthcare, this means integration into hospital systems, databases, and electronic health records across multiple stakeholders. "Every sale becomes enterprise sales" even for individual labs because of this infrastructure requirement. Founders building horizontal platforms should model sales cycles and resource requirements as enterprise from the start, regardless of deal size. Your ICP is cognitively overloaded—they won't understand your category innovation: Doctors are "under so much pressure that they just don't have any cognitive capacity left" to philosophically evaluate why AI might be difficult to implement or how infrastructure differs from technology. They need problems solved within their existing mental models. Skip the category education. Frame everything as workflow enhancement, not innovation. Let sophistication emerge through implementation, not pitch decks. Revenue doesn't equal repeatability—know when you're still in discovery mode: Despite having paying customers, Karsten explicitly states "we're not at product-market fit yet" because they're "discovering and learning things with every new laboratory hospital" around data privacy, integration, and AI deployment. The PMF signal isn't customer count or revenue—it's when the process becomes predictable, customers refer others, and you stop discovering new requirements. Hiring sales before this point scales complexity, not revenue. Regulatory friction determines market sequencing, not just market size: US governance complexity turns every deal into heavy enterprise sales with "many stakeholders," while South America proved "much more willing to move with fewer processes," making them "just much faster to adopt innovative technology." This wasn't strategy—Karsten's CTO speaks Spanish through a personal connection. But the lesson transfers: for infrastructure plays in regulated markets, test adoption velocity in lower-governance environments first to build proof points, even if TAM looks smaller on paper. In healthcare, marketing is clinical evidence—customer success creates your GTM flywheel: Karsten spends minimal time on marketing because beyond the first 5-10 users, doctors "want to see clinical evidence, they want to see papers, they want to see maybe that a friend of theirs is using it." Marketing in healthcare isn't content or demand gen—it's peer validation and published proof. Founders should structure early customer engagements to generate this evidence, not just revenue. The "marketing sales flywheel really does kick in much more once you have product market fit" because PMF enables the evidence generation required for credibility. // Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe. www.GlobalTalent.co // Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM

In this Sustainable Podcast episode by AgriBusiness Global, Jennifer Lewis, Executive Director of the International Biocontrol Manufacturers Association, discusses the significance of the European Commission's Proposal for the Simplification Package Omnibus, the reality of this speeding up the registrations process, and more.

What role are ethics provisions and stablecoin yield debates, playing in shaping — or potentially delaying — U.S. crypto market structure legislation?Gerald Gallagher is General Counsel at Sei Labs and co-host of the Crypto in America podcast, where he covers crypto policy, regulation, and legal developments in Washington.Timestamps:➡️ 1:30 — Stablecoin yield debates and why banks are back at the negotiating table➡️ 4:24 — Trade associations vs. decision-makers in White House crypto meetings➡️ 7:43 — Ethics provisions and constitutional challenges shaping negotiations➡️ 12:48 — Network token frameworks, ancillary assets, and draft bill trends➡️ 14:38 — DeFi intermediaries: software providers vs. financial actors➡️ 17:44 — Disclosure quality vs. disclosure volume in market structure drafts➡️ 21:38 — Legislation vs. agency guidance vs. litigation: three regulatory paths➡️ 24:30 — What retail users would actually notice if market structure passes➡️ 30:08 — Global competition: MiCA, Singapore MAS, and U.S. brain drain risk➡️ 43:51 — Regulatory moats, incumbents, and the future of innovationSponsor: This episode is brought to you by the Decentralization Research Center (DRC), a nonprofit think tank advocating for decentralization in emerging technologies. Learn more at thedrcenter.org.Resources:

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

As Mumbai hosted its first Climate Week, the spotlight is on how India's fast-growing cities will navigate the accelerating energy transition. Renewable power is now cheaper than ever, electric vehicles are expanding globally, and India has emerged as one of the world's largest generators of wind and solar energy. Yet the shift away from fossil fuels is proving uneven. Regulatory bottlenecks and financing gaps are slowing the pace of change even as electricity demand surges. That demand is set to climb further with the rapid expansion of AI and data centres, raising fresh questions about energy sources and long-term lock-ins. At the same time, Mumbai faces intensifying heatwaves, heavier rainfall and the long-term threat of sea-level rise, vulnerabilities that sit uneasily alongside large-scale infrastructure projects and rising air pollution levels. Urban planning choices made today, from coastal development to transport electrification, could determine whether the city builds climate resilience or compounds future risk. Can India's growth story remain compatible with its climate commitments? Will rising power demand from technology and infrastructure revive fossil fuel dependence, or accelerate clean electrification? Can India's financial capital turn climate pressure into an opportunity to lead? Guest: Helen Clarkson, CEO, Climate Group Host: Vinaya Deshpande Pandit Edited and produced by Sharmada Venkatasubramanian Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Medsider Radio, we sat down with Rick Bente, co-founder and CEO of Indomo.Indomo's flagship device, ClearPen, is an investigational at-home corticosteroid injection designed to treat inflammatory acne.Rick has over 20 years of experience as an engineer and operator across medtech and pharma, with leadership roles at Medtronic, Insulet, and YourBio, focused on drug delivery and combination products. He is an inventor on more than 50 patents and has generated over $150 million in investments.In this conversation, Rick discusses how Indomo translated an in-office dermatology procedure into at-home care, why usability had to be engineered rather than trained, how the company decided when to exit stealth mode, and how proof-based milestones shaped its fundraising.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Rick Bente.

Part II of the groundbreaking Talk Ten Tuesday series concludes as Tami McMasters Gomez returns to share the real-world impact of UC Davis Health's neurodiversity coding internship.In this powerful follow-up, Tami moves beyond the vision and into outcomes — workforce transformation, productivity gains, retention success, and the measurable value of inclusive hiring in HIM.This isn't a theory. It's operational innovation in action.If you care about strengthening the coding workforce, expanding talent pipelines, and redefining what excellence looks like in the healthcare revenue cycle, you won't want to miss this conversation.Broadcast segments will also include these instantly recognizable panelists, who will report more news during their segments:• POV: Penny Jefferson, Director of CDI Services at the University of California, Davis Medical Center, will share her point of view during the broadcast.• SDoH Report: Marie Stinebuck, CEO for Phoenix Medical Management, will report on the latest news concerning the social determinants of health (SDoH).• CDI Report: Cheryl Ericson will provide an update on clinical documentation integrity (CDI).• The Coding Report: Christine Geiger will report on the latest coding news.• News Desk: Timothy Powell, ICD10monitor national correspondent, will anchor the Talk Ten Tuesdays News Desk.

Freight Industry Warning: The February 24 edition of the AgNet News Hour tackled a topic that affects every farmer, processor, retailer, and consumer in California — freight. Hosts Nick Papagni and Josh McGill devoted the program to a candid and urgent conversation with Mark Woods and Jose Nunez of Wildwood Express, who say the state's trucking industry is approaching a critical breaking point. Woods, who operates a 45-truck fleet based in Kings County, laid out the growing list of challenges facing California freight companies: rising fuel costs, increasing insurance premiums, emissions regulations, equipment mandates, licensing issues, and deteriorating road infrastructure. While growers often talk about water, labor, and regulation, Woods emphasized that none of it matters if product can't move. “If you can't get it to market, you're dead in the water,” McGill noted — a reality that applies to almonds, tomatoes, citrus, livestock, and every other commodity grown in the state. Fuel remains one of the largest burdens. California diesel prices run significantly higher than neighboring states, and with refinery closures looming, uncertainty around supply and future pricing adds another layer of stress. Woods warned that rising transportation costs inevitably trickle down to consumers — whether it's the price of produce, meat, or a restaurant meal. Insurance is another major pressure point. Freight companies are investing in advanced safety technology — including AI-powered monitoring systems and in-cab cameras — to reduce accidents and protect drivers. Yet despite those investments, insurance costs continue climbing. Woods said companies are doing everything they can to operate safely and efficiently, but margins remain razor thin. Regulatory complexity compounds the issue. Emissions testing requirements, equipment standards, and licensing enforcement create additional compliance hurdles. Woods expressed concern that smaller operators may not survive under the weight of expanding mandates, particularly as newer truck models become more expensive. The conversation also addressed workforce challenges. While interest in commercial driving remains steady, language requirements and licensing scrutiny are impacting available drivers. Meanwhile, California's poor road conditions accelerate wear and tear on already costly equipment. Papagni underscored a critical point: everything in your home — from food to furniture — was delivered by truck. Freight is not optional. It is foundational. As Woods put it, the trucking industry isn't asking for special treatment — just a level playing field and practical policies that allow companies to remain profitable while serving California agriculture. Part two of the freight discussion continues tomorrow.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

How are these abusive teen rehab centers still open? Why are parents still sending their kids there? Can't they be shut down? Maia Szalavitz is an award-winning author and journalist who covers addiction and neuroscience. Her book, Help at Any Cost: How the Troubled-Teen Industry Cons Parents and Hurts Kids, is the first comprehensive look at systemic abuse in “tough love” programs and helped spur Congressional hearings & GAO investigations. In this episode, you'll hear how the abusive teen rehab centers featured in Netflix's The Program & Wayward (think Straight Inc., The Seed, Synanon & wilderness camps) began with tough love doctrine, why you can legally treat kids worse than prisoners, why parents aren't suing & why regulations just don't stick. We also weave in the perspective of struggling parents who feel that the anti-troubled teen industry is hurting their healing efforts.  If you like this episode, you'll also like episode 248: SURVIVING THE TROUBLED TEEN INDUSTRY: SEPARATING IDENTITY FROM EXPERIENCE [REMASTERED] Guest:https://x.com/maiasz https://maiasz.com/ Resources:Boy who was raised as a dog https://a.co/d/0bA3dxmi Pace Center for Girls Pensacola https://www.pacecenter.org/locations/florida/escambia-santa-rosa/ Gulf Coast Kids House https://www.gulfcoastkidshouse.org/ Greenhouse Counseling https://www.ghcpensacola.com/  Host:  https://www.meredithforreal.com/  https://www.instagram.com/meredithforreal/ meredith@meredithforreal.comhttps://www.youtube.com/meredithforreal  https://www.facebook.com/meredithforrealthecuriousintrovert  Sponsors: https://www.jordanharbinger.com/starterpacks/ https://www.historicpensacola.org/about-us/  02:00 — The cult origins: Synanon begins04:00 — “I must have needed that” psychology05:00 — The rattlesnake assassination attempt07:00 — The Seed and brainwashing teens08:00 — Straight Incorporated goes national10:00 — Why parents don't believe abuse reports12:00 — Utah wilderness programs rise13:00 — The death of Aaron Bacon14:00 — Moral panic & religious fear15:00 — Good parents, fatal decisions16:00 — Why regulation keeps failing17:00 — Regulatory capture in Utah20:00 — Unannounced inspections change everything22:00 — Why traumatized kids need gentleness27:00 — Warehouses of neglect28:00 — Should therapy have an FDA?29:00 — Renaming punishment as treatment32:00 — Exhausted parents & marketing fear34:00 — How small power corrupts42:00 — Why lawsuits rarely succeed44:00 — Private right of action explained45:00 — Does awareness help or hurt?46:00 — Educational consultants & kickbacks54:00 — Local resources for struggling families55:00 — Undoing drugs & keeping people aliveRequest to join my private Facebook Group, MFR Curious Insiders https://www.facebook.com/share/g/1BAt3bpwJC/

Prior authorizations among Medicare Advantage plans have drawn criticism and concern from patients, providers, lawmakers, and regulators. But hospitals and doctors are uniquely positioned to advocate for their patients' access to and coverage for care. What's necessary is the need to understand the rules of the process. And Medicare Advantage plans have many of them.During the next live edition of the venerable Monitor Monday, the Internet broadcast, Richelle Marting, a healthcare attorney, and certified coder, will help you understand when and how Medicare Advantage plans can use prior authorizations for the critical protections you need to know to advocate for patient care.Broadcast segments will also include these instantly recognizable features:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.• Legislative Update: Matthew Albright of Zelis, will report on current healthcare legislation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of these industries, exploring significant regulatory shifts, scientific breakthroughs, and strategic corporate maneuvers that are shaping the future of healthcare.The pharmaceutical and biotech sectors are currently navigating a period of profound transition. Recent regulatory developments have captured attention, particularly the U.S. Supreme Court's decision to overturn emergency tariffs imposed by the previous administration. This ruling is pivotal as it alleviates financial pressures on the industry, allowing companies to redirect their resources towards innovation and development. It underscores the interconnectedness of global supply chains and highlights the importance of stable regulatory environments for fostering industry growth.In a notable advancement within oncology, AstraZeneca has achieved FDA approval for its combination therapy of Calquence and Venclexta as an all-oral regimen for first-line chronic lymphocytic leukemia (CLL). This approval not only positions AstraZeneca competitively in the BTK inhibitor market but also signifies a shift towards more patient-friendly treatment regimens. By simplifying therapy, this development promises to enhance patient compliance and improve outcomes, challenging existing standards in CLL care.Meanwhile, internal challenges at the Centers for Disease Control and Prevention have led to a postponement of a critical vaccine advisory panel meeting. This delay occurs amid evolving vaccine policies that have sparked debate within the public health community, potentially impacting immunization strategies and initiatives aimed at bolstering public health.Corporate governance within the industry is also experiencing shifts. Novo Nordisk has nominated two industry veterans to its board as part of an ongoing strategy to align leadership with evolving business objectives. Similarly, Roche is contemplating divesting its once-blockbuster antibiotic Rocephin in response to competitive pressures from generics in Europe. These moves reflect a broader industry trend where companies are re-evaluating their portfolios to better respond to market dynamics and patent expirations.Novartis is making strategic changes as well by selling its stake in Novartis India Limited while maintaining separate commercial and R&D interests in the region. This action highlights a growing trend among pharmaceutical giants towards streamlining operations and focusing on high-growth areas—a strategy aimed at maximizing resource allocation efficiency.Despite narrowly missing a $1 billion revenue target for 2025, Madrigal Pharmaceuticals remains optimistic about the growth prospects of its drug Rezdiifra within the metabolic dysfunction-associated steatohepatitis (MASH) market. The company anticipates further expansion driven by unmet medical needs, underscoring the competitive dynamics within this therapeutic area.In personnel movements that could influence strategic directions, Daiichi Sankyo has appointed former Novartis CMO John Tsai as head of its R&D division. His expertise is expected to bolster Daiichi's focus on oncology and other critical therapeutic areas, potentially accelerating innovation within their drug development pipeline.Meanwhile, Manus Bio has secured a $15 million contract with the U.S. government for domestic supply of shikimic acid, an essential component for producing Tamiflu. This contract highlights efforts to strengthen domestic pharmaceutical supply chains amid global uncertainties—a crucial consideration for ensuring medication availability during crises.In clinical research, a setback was observed with Grail's Galleri cancer blood test trial failing to meet its primary endpoint in collaboration with the NHS. The resulting decline in GrailSupport the show

Anthony Scaramucci is the founder and managing partner of SkyBridge Capital and a longtime macro investor at the intersection of traditional finance, crypto, and politics. This conversation was recorded live at Bitcoin Investor Week in New York. In this conversation, Scaramucci shares his candid views on Trump, crypto regulation, why the Clarity Act is critical for the industry, SkyBridge's shift toward bitcoin, his early role in the BlackRock Bitcoin ETF, and why progress in Washington requires compromise. He also explains how demographics, regulation, and capital allocation shape bitcoin's long-term future.======================This podcast is sponsored by Abra.com. Abra is the secure way to access crypto and crypto based yield and loan products through a separately managed account structure.Learn more at ⁠http://www.abra.com⁠.======================⁠BitcoinIRA⁠: Buy, sell, and swap 80+ cryptocurrencies in your retirement account. Take 3 minutes to open your account & get connected to a team of IRA specialists that will guide you through every step of the process. Go to ⁠https://bitcoinira.com/pomp/⁠ to earn up to $1,000 in rewards.======================As markets shift, headlines break, and interest rates swing, one thing stays true — opportunity is everywhere. At Arch Public, we help you do more than just buy and hold. Yes, our dynamic accumulation algorithms are built for long-term investors… but where we really shine? Our arbitrage algos — designed to farm volatility and turbocharge your core positions. The best part of Arch Public's products is they are free! Yes, you heard that right, try Arch Public for free! Take advantage of wild moves in assets like $SOL, $SUI, and $DOGE, and use them to stack more Bitcoin — completely hands-free. Arch Public is already a preferred partner with Coinbase, Kraken, Gemini, and Robinhood, and our team is here to help you build smarter in any market. Visit Arch Public today, at ⁠https://www.archpublic.com⁠, your portfolio will thank you.======================0:00 - Intro0:20 - Trump, politics & crypto context4:12 - Why crypto regulation will pass7:45 - Inside the BlackRock bitcoin ETF origin story11:52 - SkyBridge's pivot to bitcoin 18:17 - Biggest risk to bitcoin: demographics & old money20:38 - Scaramucci's politics podcast & final thoughts

In this episode, Elliot Berman and John Byrne break down the major developments from the February FATF Plenary, including Kuwait and Papua New Guinea joining the Grey List and updates on evaluations for Austria, Italy, and Singapore. They also explore FATF leadership changes and the reiteration of Russia's suspension. The conversation moves into rising crypto-enabled human trafficking networks highlighted in a new report from Chainalysis, Cambodia's large-scale crackdown on fraud centers, and several key U.S. regulatory updates. These include FinCEN's new CDD “exceptive relief,” the rollout of a whistleblower portal, and the OCC's proposed changes to the bank appeals process. Elliot and John also discuss recent law enforcement actions, Supreme Court efforts to strengthen conflict-of-interest checks, and a Federal Reserve governor's insight into how AI may reshape the labor market.

AAF President Douglas Holtz-Eakin, Director of Regulatory Policy Dan Goldbeck, and Director of Health Care Policy Michael Baker join us to discuss the latest on the economy, Trump's regulatory agenda, and health policy. Apple: podcasts.apple.com/us/podcast/the-…st/id1462191777 Spotify: open.spotify.com/show/7aWwYw3EKPmTqLQMbRGR2e

Bob Zimmerman covers ESA's fast-tracked Apophis asteroid mission, a commercial attempt to rescue a NASAtelescope, and the contrasting regulatory environments of the UK and New Zealand for space launches.

Guest: Bob Zimmerman. Musk announces SpaceX will prioritize the Moon before Mars; regulatory approvals for Starship launches are pending, while Voyager Space secures a management contract for ISS operations.1906. WELLS. MARTIAN